TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Motor assessment scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete Jebsen Taylor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average reading time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High frequency (HF) band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low frequency (LF) band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Consumption of 5 or more servings of fruits and vegetables daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to physical activity guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: fewer reported sleep-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: average nightly CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within two years
Endpoint domain: Mortality/survival
Primary endpoint: ΔEWSL/SAE units of available teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restoration survival percentage
Endpoint domain: Mortality/survival
Primary endpoint: cost-effectiveness ratio
Endpoint domain: Resource use
Primary endpoint: VISA-A score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients completely pain-free
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Sagittal tendon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False Positive Fail Calls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resident performance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of practice with published standards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive impairment measured by MMSE score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Differentiation of benign from malignant oncocytic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: language improvement in category judgment task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: language improvement in letter fluency task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 1/2 RPV-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mean maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the concentration-time curve (28 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: onset of amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of motor cranial nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pancreatic stump-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of urinary incontinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MMR achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MR(4.0) achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MR(4.5) achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Willingness to take the solution again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decline in physical health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor outcome on mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased cost in primary care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wexner's FI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective ratings of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective detection of malodour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lean body mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total fat mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total bone mineral content change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical response (cured/improved/failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid temperature decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of leakage episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway management technique used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cough
Endpoint domain: Adverse events/effects
Primary endpoint: Hypersalivation
Endpoint domain: Adverse events/effects
Primary endpoint: Upper airway obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum levels of NFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual attention (TMT‐A score change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative symptoms score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAI fibrosis staging improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: average bleeding duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of cases with bleeding amount less than normal menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary miosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strengths in MPa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: agitation/aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eating/appetite disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduced analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faster return to normal domestic activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: severe toxicity (enteritis)
Endpoint domain: Adverse events/effects
Primary endpoint: CT-related death (gastrointestinal bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: safety and tolerability of sacubitril/valsartan
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy of sacubitril/valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall response rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment completion prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical hypoglycemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Digoxin renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of change of Vmax in patients with aortic valve sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival without progressive disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of aphereses required to collect PBPCs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD34+ cells yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulocyte-macrophage colony-forming cells (GM-CFCs) yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suicide attempt rate
Endpoint domain: Mortality/survival
Primary endpoint: skin barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mortality risk associated with dietary supplement use
Endpoint domain: Mortality/survival
Primary endpoint: Recall of targeted medication information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved NKCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased postoperative infectious illnesses
Endpoint domain: Adverse events/effects
Primary endpoint: desire for pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: attitudes toward father/child involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in dsDNA antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient sensory deficits
Endpoint domain: Adverse events/effects
Primary endpoint: Polymorphonuclear (PMN) collection efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total PMN yield per liter of blood processed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulocyte viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset time of the antifebrile effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative time for rash disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative time for mouth ulcers disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy drinking days during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative mood changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Test scores using question format
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for question format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficiency of question format
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AOPP levels post exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GSH levels post exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harris functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐treatment symptom improving rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hematologic and hemorrheologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: dental calculus index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: sick-leave days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum lithium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in affective and psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hyperchloremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Facial symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis and management of postnatal depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilaterally absent N20 waves predicting permanent coma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: requirement for rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory hearing at 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-of-ATI viral load (VL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: multifunctional cytotoxic T-lymphocyte responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adverse events (local injection site reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: engagement in paid activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: total hours worked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: total wages earned
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Aqueous humor concentration of gatifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological activity against S. epidermidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to dehydroepiandrosterone treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of postoperative atrial fibrillation (POAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UTD status achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation rates for immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per child for immunization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbial colonisation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: steps taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-CPSI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving IGA success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of glottis opening score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of LBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative troponin I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurologic event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: repeat revascularization procedures due to restenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Stress-coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adjusted mean cost of the acute care episode
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Readmission within 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of the day spent sedentary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MACawake of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum neuron-specific enolase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in metastatic disease at diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Clinically acceptable intubation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parent-reported inattention and hyperactive/impulsive difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients performing optimum inhalation profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial blood glucose (PBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HBAIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting blood glucose (FBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of RAO at 1-year after TRI
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of local vascular complications during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: DHEA-S levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 7-day tobacco abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported continuous abstinence rates for 6 months after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Time interval for receipt of data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in left ventricular end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success of H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete drug compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of acute renal failure
Endpoint domain: Adverse events/effects
Primary endpoint: elevation of the resistive index of the hepatic arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean portal venous flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of documented infections
Endpoint domain: Adverse events/effects
Primary endpoint: mechanical complications
Endpoint domain: Adverse events/effects
Primary endpoint: thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of correctly identified depression cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practitioners' competence in case identification and treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in LVEF after BMC treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FEV1/FVC%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of the digital system in detecting threshold events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Specificity of the digital system in detecting threshold events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Positive predictive value of the digital system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes